Introduction
============

Acylated (AG) and unacylated ghrelin (UAG) are circulating peptides encoded by the preproghrelin gene peptides and are mainly secreted by the X/A-like enteroendocrine cells of the stomach ([@bib16], [@bib20]). AG stimulates growth hormone (GH) release and positive energy balance by binding in the hypothalamus and pituitary gland to the only functional ghrelin receptor that has been characterized thus far, GH secretagogue receptor 1a (GHSR1a) ([@bib12], [@bib1], [@bib20]). The presence of an acyl side chain (mainly *n*-octanoic acid) attached to the AG peptide is required for full agonism of GHSR1a ([@bib1], [@bib11], [@bib15]).

In addition to the gut, AG and GHSR1a were expressed in mammary glands and cultured primary mammary epithelial cells (MECs) ([@bib36], [@bib14], [@bib23]). Therefore, understanding the regulating actions of these peptides is of interest. AG has a speciﬁc action during lactation. In addition to increasing plasma insulin, food intake, and glucose concentrations ([@bib13], [@bib7]), AG also affects milk production and milk components in rats and dairy cows ([@bib22]) and affects milk fat and protein synthesis in water buffaloes ([@bib9]). β-casein (CSN2) is the most abundant protein in cow milk and is often used as a marker for mammary differentiation. CSN2 was previously shown to be expressed under *in vitro* conditions in different species, such as in several bovine mammary cell lines ([@bib14]), goat primary mammary cells ([@bib36], [@bib23]), and mammary gland explants from cows. Northern blot analysis revealed that daily injection of AG signiﬁcantly increased mammary gland *CSN2* mRNA expression in rats ([@bib22]). Zhang and colleagues showed that levels of CSN2 protein increased in MECs of lactating goat after treated with AG compared with control group ([@bib36]). However, the effects and mechanisms of AG in milk protein synthesis in primary bovine mammary epithelial cells (pbMECs) have not been examined.

A number of reports have been published on the regulation of AG secretion in the context of energy metabolism that did not distinguish between acyl-modified and des-acyl AG ([@bib29], [@bib5], [@bib24]). In contrast to AG, the regulating action of UAG in the expression of CSN2 remains poorly understood. In several studies, the effects of AG are mimicked by UAG ([@bib10], [@bib25]). Later studies revealed a weak but full agonism of binding by UAG to GHSR1a ([@bib8], [@bib11]). However, the potential role of UAG in the expression of CSN2 in pbMECs has yet to be identified. Moreover, whether UAG can activate a similar pathway to AG to regulate the expression of CSN2 is not clear.

G-protein-coupled receptors (GPCRs) are one of the major classes of cell surface receptors and are associated with a group of G-proteins consisting of three subunits termed alpha, beta, and gamma. G-proteins are classiﬁed into four families according to their α subunit: Gi alpha subunit (Gαi), Gs alpha subunit (Gαs), G12/G13 alpha subunits (Gα12/13), and Gq alpha subunit (Gαq). Attempts to elucidate the peripheral effects of AG have identified several signaling mechanisms involving G-protein-dependent pathways, highlighting the complexity of GHSR1a activation ([@bib6], [@bib15], [@bib32]). Depending on the tissues and cells, activation of GHSR1a may trigger a diverse signaling mechanism and subsequently distinct physiological responses. Both AG and UAG stimulate cell proliferation and prevent apoptosis via activation of the ERK1/2 and AKT pathways in different cells, such as pancreatic β-cells, skeletal muscle cells ([@bib25], [@bib34]), and human endothelial cells ([@bib31]). In addition, both pbMEC number and activity can be affected by IGF-I signaling by activating the AKT and ERK1/2 pathways. Moreover, the AKT pathway is activated in response to milk yield ([@bib21]). However, whether AG and UAG activate the ERK1/2 and AKT pathways and induce the expression of CSN2 via GHSR1a in pbMECs of lactating cows is not known.

The aim of this study was to evaluate the effects of AG and UAG on the expression of CSN2 in pbMECs of lactating cows. Furthermore, the signal pathways that are involved in the expression of CSN2 induced by both AG and UAG were also investigated.

Materials and methods
=====================

Reagents
--------

Human AG (Ser3-Decanoyl), Human UAG (Ser3-Des-Octanoyl), and \[D-Lys3\]-GHRP-6 were obtained from Phoenix Pharmaceuticals, Inc. (Belmont, CA, USA). Antibodies to P-ERK 1/2 (Thr202/Tyr204), ERK1/2 (Thr202/Tyr204), AKT(Ser473), and P-AKT (Ser473) were purchased from Cell Signaling Technology Inc. Antibodies to AG, GHSR1a, and CSN2 were purchased from Abcam. Bovine insulin, prolactin, hydrocortisone, phosphatase inhibitor cocktail 2, protease inhibitor cocktail, and DAPI were obtained from Sigma. The antibodies for goat anti-rabbit IgG-HRP, rabbit anti-cytokeratin 18 (CK-18), and rabbit anti-β-tubulin (1--19) were purchased from Santa Cruz Biotechnology. The selective inhibitors of NF449 (Gαs), pertussis toxin (PTX, Gαi), and U0126 (ERK 1/2) were obtained from TOCRIS (Ellisville, MO, USA). The selective inhibitor of YM-254890 (Gq11) was provided by Astellas Pharma Inc. (Tokyo, Japan). The selective inhibitor of MK2206 (AKT) was from Selleckchem (Houston, DE, USA).

PbMECs cultures and treatments
------------------------------

PbMECs from the alveolar tissue of four mid-lactation (d 150--200 after parturition) from healthy Holstein cows were isolated using a procedure described previously ([@bib28], [@bib14]). Cells were maintained in DMEM-F12, supplemented with 10% fetal bovine serum, penicillin (100 µ/mL), streptomycin (100 mg/mL), bovine insulin (5 μg/mL), hydrocortisone (1 μg/mL), and prolactin (1 μg/mL). The expression of CK-18 was identified as a marker of pbMECs by both immunofluorescence and flow cytometry. The gene expression of *CSN2*, ghrelin (*GHRL*), and *GHSR1a* were detected by quantitative RT-PCR and western blot in pbMECs from passages 1--4.

The cells were treated with increasing concentrations of AG or UAG (0, 0.01, 0.1, 1, 10, and 100 ng/mL) for 12 or 24 h. The cells were then collected and frozen at −80°C until mRNA or protein extraction. For some experiments, the cells were pre-incubated with inhibitors for 1 h, and then treated for different time periods with AG or UAG.

Quantitative RT-PCR
-------------------

After treatment with AG or UAG for different time periods, the pbMECs were harvested. Total RNA was extracted from pbMECs and reversed transcribed into cDNA from 4 μg total RNA, as described previously ([@bib18]). The mRNA levels of various genes were evaluated using the SYBR Green QuantiTect RT-PCR Kit. The comparative 2^−ΔΔct^ method was used to calculate the relative gene expression levels of *CSN2*, *GHRL*, and *GHSR1a*, with β-actin serving as the housekeeping gene. The PCR products were visualiz­ed via 1.5% agarose gel electrophoresis. The following primers were used: GHSR1a, 5′-CCGACAATGACTCGCTGACT-3′ and 5′-CAAGTTCCAGGGCCGGTAAT-3′; GHR, 5′-ATGCCCGCCCCGTGGACCAT-3′ and 5′-AACCGGATTTCCAGCTCGTC-3′; CSN2, 5′-GGCTATGGCTCCTAAGCACA-3′ and 5′-GAGAAAGGGACAGCACGGAC-3′; and β-actin, 5′-TCACCAACTGGGACGACA-3′ and 5′-GCATACAGGGACAGCACA-3′.

Western blot analysis
---------------------

After treatment with AG or UAG for different time periods, whole-cell proteins were extracted in accordance with our published protocol ([@bib18]). The cells were washed with ice-cold PBS and harvested using RIPA lysis buffer containing 10 mM HEPES, pH 7.5; 10 mM KCl; 0.1 mM EGTA; 0.1 mM EDTA; phosphatase inhibitor cocktail 2, and protease inhibitor cocktail. Protein samples (40 μg) were subjected to 12% SDS--PAGE and transferred to PVDF membrane (Chemicon International, Millipore, Billerica, MA, USA). After blocking with 5% milk, the membranes were incubated overnight at 4°C with the specific antibodies to P-ERK1/2 (1:1000), ERK1/2 (1:2000), AKT (1:2000), P-AKT (1:1000), GHSR1a (1:4000), CSN2 (1:1000), AG (1:500), or β-tubulin (1:10,000). The membranes were washed four times with 0.1% TBS-T and incubated with goat anti-rabbit IgG-HRP for 1 h at room temperature (RT). The immunoreactive proteins were visualized using the ECL detection system (Millipore).

Cell viability assay
--------------------

Cells were seeded in 96-well plates at a density of 5 × 10^4^ cells/well and treated with AG or UAG (0, 0.01, 0.1, 1, 10, and 100 ng/mL) for 24, 48, and 72 h. After treatment, the cells were incubated with 1 mg/mL MTT for approximately 4 h and then incubated with 150 μL of dimethylsulfoxide for 10 min. The optical density of the samples was quantified by measuring the absorbance at 570 nm and expressed as the percentage relative to the untreated control. Each experiment included five replicates per treatment, and the experiments were repeated a minimum of three times. For some experiments, the cells were pre-incubated with inhibitors for 1 h and then treated for 24 h with AG or UAG.

Immunofluorescence assay
------------------------

To evaluate the expression of CK-18 in pbMECs, 1 × 10^4^ cells/well were seeded in a slide in 24-well plates for 24 h. Slides were ﬁxed with 4% paraformaldehyde in PBS for 10 min at RT. After blocking with 3% normal goat serum for 2 h at RT, the slides were incubated with primary antibodies to CK-18 (1:200) overnight at 4°C. After washing, the slides were incubated with PE-conjugated goat anti-rabbit IgG (1:500) for 1 h at RT. DAPI was used to stain the cell nuclei at a concentration of 1.43 µM for 10 min. After staining, slides were viewed with an inverted fluorescence microscope.

Flow cytometry assay
--------------------

To evaluate the population of CK-18-expressing pbMECs, the cells were seeded into 6-well plates at a density of 1 × 10^6^ cells/well. After 24 h, the cells were aspirated and washed with PBS twice. After blocking, the cells were stained with CK-18 (1:500) for 16 h at 4°C. The cells were incubated with donkey anti-rabbit IgG-FITC for 1 h at RT after washing. Flow cytometry (BD Biosciences, USA) was used to determine the population of CK-18^+^ cells.

Statistical analysis
--------------------

The data were analyzed using GraphPad Prism 5 (GraphPad InStat Software, San Diego, CA, USA). The comparison among groups was carried with an ANOVA followed by Dunnett's test. In each panel, experiments were repeated with similar results at least three times. Data are presented as the mean ± s.d. A *P*-value of 0.05 or 0.01 was considered statistically significant.

Results
=======

AG and UAG promote the expression of CSN2 in pbMECs
---------------------------------------------------

We first detected the morphology ([Fig. 1A](#fig1){ref-type="fig"}) and the expression of CK-18 before each experiment to ensure the purity of pbMECs. Cells from a population with 99% CK-18 expression were used in the subsequent experiments ([Fig. 1B and C](#fig1){ref-type="fig"}). We next detected the expression of CSN2, AG, and GHSR1a in cultured pbMECs from passage 1 to passage 4. The results showed that genes of *CSN2*, *GHRL*, and *GHSR1a* were expressed at passages 1--4, although the gene level was lower at passage 1 and passage 2 ([Fig. 1D](#fig1){ref-type="fig"}). Moreover, the proteins of CSN2, AG, and GHSR1a were also stably expressed in pbMECs at passages 1--4 ([Fig. 1E](#fig1){ref-type="fig"}). Figure 1Cultured and detection of pbMECs. (A) Morphology of cultured pbMECs. Islands of epithelial cells are visible (bar = 1000 μm). (B) The expression of CK-18 in pbMECs was studied by flow cytometry. (C) Immunofluorescence labeling of CK-18 in pbMECs (200× magnification). (D) Gene expression of *CNS2, GHSR1a*, and *GHRL* in cultured pbMECs (passages 1-4). (E) Protein expression of CSN2, AG, and GHSR1a in pbMECs (passages 1-4). A full colour version of this figure is available at <http://dx.doi.org/10.1530/JME-15-0287>.

Previous studies showed that AG increases *CSN2* mRNA expression in MECs from dairy goats ([@bib36]). However, whether AG influences the expression of CSN2 in pbMECs is not known. In addition, UAG is a weaker agonist of GHSR1a compared with AG ([@bib8]). Therefore, we hypothesized that treatment with UAG has similar but maybe less potent effects than AG on the expression of CSN2. To test this hypothesis, the gene and protein expression of CSN2 were detected after treatment for 12 or 24 h with increasing concentrations of either AG or UAG in pbMECs. The results showed that compared with the non-treated (NT) control group, only 10 ng/mL AG or UAG significantly increased *CSN2* gene expression ([Fig. 2A, B and C](#fig2){ref-type="fig"}). Western blot results showed that the expression of CSN2 protein was significantly higher in these pbMECs treated with AG (1--100 ng/mL) and peaked at 10 ng/mL and then decreased at 100 ng/mL (*P* \< 0.01; [Fig. 2B, C and D](#fig2){ref-type="fig"}). For UAG treatment at 10 ng/mL and 100 ng/mL, significantly higher values of protein expression of CSN2 were observed (*P* \< 0.01; [Fig. 2B, C and D](#fig2){ref-type="fig"}). In addition, we also investigated whether AG and UAG influences the expression of GHSR1a in pbMECs. Our results showed that both AG and UAG have no significant effect on GHSR1a gene and protein expression ([Supplementary Figure 1](jme-56-213-s001.jpg), see section on [supplementary data](#supp1){ref-type="sec"} given at the end of this article). Considering the above results, 10 ng/mL was selected as the best concentration for AG and UAG in subsequent experiments. Figure 2AG and UAG induce CSN2 gene and protein expression in pbMECs. (A) Cells were incubated for 12 h with increasing concentrations of AG or UAG. Gene expression of *CSN2* was determined by quantitative RT-PCR. (B) Cells were incubated for 24 h with increasing concentrations of AG or UAG. Protein expression of CSN2 was examined by western blot. (C and D) The data are presented as the mean ± S.D. (*n* \> 3 independent experiments; \**P* \< 0.05, \*\**P* \< 0.01 vs non-treated (NT) control group).

GHSR1a and Gαs are required for AG- and UAG-induced expression of CSN2 in pbMECs
--------------------------------------------------------------------------------

Previous research reported that both AG and UAG regulate peripheral glucose metabolism through a GHSR1a-dependent mechanism ([@bib11]). \[D-Lys3\]-GHRP-6 is regarded as a highly selective GHSR1a antagonist and has been widely used to investigate the dependency of GHSR1a signaling ([@bib10], [@bib36]). To determine whether the effect of AG and UAG on the expression of CSN2 depends on GHSR1a activation, pbMECs were pre-incubated with \[D-Lys3\]-GHRP-6 (100 μg/mL) for 1 h, followed with AG or UAG for 24 h. The results showed that both AG and UAG significantly increased gene and protein expression of CSN2 in pbMECs compared with the NT control group ([Fig. 3A, B, C, D, E, F, G, and H](#fig3){ref-type="fig"}). However, the increased gene level of *CSN2* was inhibited by \[D-Lys3\]-GHRP-6 (*P* \< 0.01; [Fig. 3A, B, E, and F](#fig3){ref-type="fig"}). Moreover, increased protein level of CSN2 was also suppressed by \[D-Lys3\]-GHRP-6 (*P* \< 0.01; [Fig. 3C, D, G, and H](#fig3){ref-type="fig"}). However, stimulation with \[D-Lys3\]-GHRP-6 alone had no significant effects on the expression of CSN2 compared with the NT control group. Figure 3AG and UAG increased the expression of CSN2 in a GHSR1a-dependent manner in pbMECs. The cells were pre-treated for 1 h with \[D-Lys3\]-GHRP-6 (100 μg/mL) and then incubated for 12 or 24 h with AG or UAG. The gene and protein expression of CSN2 was examined by (A and B) quantitative RT-PCR and (C and D) western blot. (E, F, G, and H) The data are presented as the mean ± S.D. (*n* \> 3 independent experiments; \#*P* \< 0.01 vs NT; \**P* \< 0.05, \*\**P* \< 0.01 vs AG or UAG treatment).

AG binding to GHSR1a has been shown to activate intracellular second messengers coupled to Gαs, Gαi/o, and Gαq/11 and enhanced GH release, appetite, and proliferation ([@bib10], [@bib6], [@bib25]). GHSR1a couples to different intracellular signaling pathways and mediates different effects depending on the cell type. However, which G-protein subunits couple to GHSR1a to mediate the effect of AG or UAG in pbMECs remains unknown. To investigate this mechanism, the cells were pre-incubated for 1 h with NF449 (10 μM), YM254890 (10 μM), and PTX (10 μM), which are selective Gαs, Gq/11, and Gi/o protein-coupled receptor antagonists respectively. Next, the cells were incubated for 12 or 24 h with AG or UAG. Pre-incubation with NF449 resulted in a complete blockade of both AG- and UAG-induced gene and protein expression of CSN2 (*P* \< 0.01; [Fig. 4A, B, C, D, E, F, G, and H](#fig4){ref-type="fig"}). However, treatment with PTX and YM-254890 had no effect on both AG- and UAG-induced mRNA and protein expression of CSN2 in pbMECs ([Supplementary Figure 2](jme-56-213-s002.jpg)). These results implied that activation of GHSR1a by AG and UAG is likely coupled to Gαs, not Gq/11 and Gi/o, and promotes the expression of CSN2 in pbMECs. Figure 4Gαs is coupled to GHSR and is required for AG- and UAG-induced expression of CSN2 in pbMECs. The cells were pre-treated for 1 h with NF449 (10 μM) and then incubated for 12 or 24 h with AG or UAG. The gene and protein expression of CSN2 was examined by (A and B) quantitative RT-PCR and (C and D) western blot. (E, F, G, and H) The data are presented as the mean ± S.D. (*n* \> 3 independent experiments; \#*P* \< 0.01 vs NT; \**P* \< 0.05, \*\**P* \< 0.01 vs AG or UAG treatment).

AG and UAG induce ERK1/2 and AKT phosphorylation in pbMECs via activation of GHSR1a and Gαs
-------------------------------------------------------------------------------------------

Recent studies have demonstrated that under deﬁned conditions, GHSR1a couples to Gαs, resulting in activation of phospho-ERK1/2 and phospho-AKT ([@bib10], [@bib6], [@bib15]). Thus, we next assessed the potential role of GHSR1a in regulating the activation of ERK1/2 and AKT signaling in pbMECs. The cells were pre-incubated with \[D-Lys3\]-GHRP-6 for 1 h and followed with AG or UAG for 5, 30, and 60 min. After treatment with AG, the phosphorylation of ERK1/2 and AKT was significantly increased compared with the NT control group but suppressed after pre-incubation with \[D-Lys3\]-GHRP-6 at 60 min for phospho-ERK1/2, or 5 and 60 min for phospho-AKT, respectively (*P* \< 0.01; [Fig. 5A, C, and D](#fig5){ref-type="fig"}). In addition, the increased phosphorylation of ERK1/2 and AKT induced by UAG was also blocked by \[D-Lys3\]-GHRP-6 at 5 min for phospho-ERK1/2 and phospho-AKT compared to with the NT control group, respectively (*P* \< 0.01; [Fig. 5B, E, and F](#fig5){ref-type="fig"}). Figure 5AG and UAG induce ERK1/2 and AKT phosphorylation in GHSR-dependent manner in pbMECs. Cultured pbMECs were incubated with either AG or UAG in the presence or absence of \[D-Lys3\]-GHRP-6 (100 μg/mL) for 5, 30, and 60 min. At the indicated time points, cell lysates were prepared and subjected to western blotting using ERK1/2, P-ERK1/2, AKT, and P-AKT antibodies. (A and B) AG- and UAG-induced phosphorylation of ERK1/2 and AKT were abolished upon treatment with \[D-Lys3\]-GHRP-6. (C, D, E, and F) Bar graph showing mean of P-ERK1/2 and P-AKT levels. (*n* \> 3 independent experiments; \#*P* \< 0.01 vs NT; \**P* \< 0.05, \*\**P* \< 0.01 vs AG or UAG treatment).

Our previous results showed that AG- and UAG-induced expression of CSN2 involves a Gαs protein-coupled receptor, which, in turn, has been shown to activate ERK1/2 and AKT signaling ([@bib10], [@bib34]). Therefore, we investigated whether these pathways mediate the increased expression of CSN2 induced by AG or UAG. In agreement, NF449 also inhibited AG-induced ERK1/2 phosphorylation at 30 and 60 min (*P* \< 0.01; [Fig. 6A and C](#fig6){ref-type="fig"}), and increased phospho-AKT was also suppressed by NF449 at 5, 30, and 60 min (*P* \< 0.01; [Fig. 6A and D](#fig6){ref-type="fig"}). In addition, stimulation of pbMECs with UAG leads to significantly increased phosphorylation of ERK1/2, which is reduced by NF449 at 5, 30, and 60 min (*P* \< 0.01; [Fig. 6B and E](#fig6){ref-type="fig"}). Moreover, induced phospho-AKT was also decreased at 30 min (*P* \< 0.01; [Fig. 6B and F](#fig6){ref-type="fig"}); however, no effect was found using inhibitors alone. These results suggested that GHSR1a and Gαs are required for AG- and UAG-induced phosphorylation of ERK1/2 and AKT in pbMECs. Figure 6Gαs is required for ERK1/2 and AKT phosphorylation induced by AG or UAG in pbMECs. Cells were incubated with either AG or UAG in the presence or absence of NF449 (10 μM) for 5, 30, and 60 min. At the indicated time points, cell lysates were prepared and subjected to western blotting using ERK1/2, P-ERK1/2, AKT, and P-AKT antibodies. (A and B) Phosphorylation of ERK1/2 and AKT activated by AG or UAG was inhibited by NF449, a Gαs subunit-selective G-protein antagonist. (C, D, E, and F) Bar graph showing mean of P-ERK1/2 and P-AKT levels. (*n* \> 3 independent experiments; \#*P* \< 0.01 vs NT; \**P* \< 0.05, \*\**P* \< 0.01 vs AG or UAG treatment).

AG and UAG stimulate the expression of CSN2 by activating ERK1/2 and AKT signaling
----------------------------------------------------------------------------------

To further determine the potential role of ERK1/2 and AKT pathways in AG- and UAG-induced expression of CSN2 in pbMECs, the cells were pre-incubated for 1 h with U0126 and MK2206, which are specific inhibitors of ERK1/2 and AKT respectively. Our results showed that treatment with U0126 resulted in a significant blockade of ERK1/2 phosphorylation (data not shown). The gene and protein levels of CSN2 induced by AG and UAG were also inhibited by U0126 in pbMECs (*P* \< 0.01; [Fig. 7](#fig7){ref-type="fig"}). In addition, stimulated with MK2206 for 1 h completely blockaded the phosphorylation of AKT in pbMECs (data not shown). Increased gene and protein expression of CSN2 was also suppressed by MK2206 in pbMECs (*P* \< 0.01; [Fig. 8](#fig8){ref-type="fig"}). However, stimulation with U0126 and MK2206 alone had no significant effects on the expression of CSN2 compared with the NT control group. Together, these results demonstrated that AG- and UAG-induced expression of CSN2 might depend on the phosphorylation of ERK1/2 and AKT in pbMECs. Figure 7AG and UAG induce the expression of CSN2 through the ERK1/2 signaling pathway in pbMECs. The cells were pre-treated for 1 h with U0126 (10 μM), followed by AG or UAG for 12 or 24 h. The gene and protein expression of CSN2 was examined by (A and B) quantitative RT-PCR and (C and D) western blot. (E, F, G and H) The data are presented as the mean ± S.D. (*n* \> 3 independent experiments; \#*P* \< 0.01 vs NT; \**P* \< 0.05, \*\**P* \< 0.01 vs AG or UAG treatment). Figure 8AG and UAG induce the expression of CSN2 through the AKT signaling pathway in pbMECs. The cells were pre-treated for 1 h with MK2206 (10 μM), followed by AG or UAG for 12 or 24 h. The gene and protein expression of CSN2 were examined by (E and F) quantitative RT-PCR and (A and B) western blot (C and D). (E, F, G, and H) The data are presented as the mean ± S.D. (*n* \> 3 independent experiments; \#*P* \< 0.01 vs NT; \**P* \< 0.05, \*\**P* \< 0.01 vs AG or UAG treatment).

AG and UAG stimulate cell proliferation in pbMECs
-------------------------------------------------

Both AG and UAG not only stimulated cell proliferation but also suppressed apoptosis in pancreatic β-cells, skeletal muscle, and macrophages ([@bib8], [@bib6], [@bib19]). Thus, finally, we investigated the effects of increasing the concentration of AG and UAG treatment on the growth of pbMECs. As shown in [Fig. 9](#fig1){ref-type="fig"}, compared with the NT control group, pbMECs proliferation was enhanced following increased AG stimulation for 24, 48, and 72 h, with the maximum proliferative response at 100 ng/mL (*P* \< 0.05; [Fig. 9A](#fig9){ref-type="fig"}). In addition, UAG significantly induced cell proliferation in a dose-dependent manner at 24 h, and was lower but still above basal level after 48 and 72 h (*P* \< 0.05; [Fig. 9B](#fig9){ref-type="fig"}). These results suggested that cell proliferation was markedly enhanced as the concentration of AG and UAG. However, there were no cytotoxic effects on the growth of pbMECs. Figure 9AG and UAG induce pbMEC proliferation. PbMECs were cultured with increasing concentrations of AG or UAG for 24, 48, and 72 h with or without AG or UAG. Then, cell proliferation was measured in a MTT assay. (A and B) AG and UAG markedly enhanced cell proliferation at 24, 48, or 72 h. The cells were pre-treated for 1 h with D-Lys, NF449, U0126, or MK2206, followed by AG or UAG for 24 and 48 h. (C and D) AG- and UAG-induced cell proliferation were inhibited by D-Lys, NF449, U0126, or MK2206. Values are presented as the mean ± S.D. (*n* \> 3 independent experiments; \#*P* \< 0.01 vs NT; \**P* \< 0.05, \*\**P* \< 0.01 vs AG or UAG treatment).

To examine whether GHSR1a and Gαs mediate AG- and UAG-induced proliferation in pbMECs, the cells were pre-incubated with \[D-Lys3\]-GHRP-6 and NF449 for 1 h followed by incubation with AG or UAG. The results showed that pre-incubation with \[D-Lys3\]-GHRP-6 or NF449 remarkably reduced AG- or UAG-induced proliferation in pbMECs compared with AG or UAG group (*P* \< 0.05; [Fig. 9C and D](#fig9){ref-type="fig"}). To elucidate whether activation of the ERK1/2 and AKT pathways are required to AG- and UAG-induced proliferation, we assessed the effect of U0126 and MK2206. Both AG- and UAG-induced cell proliferations were blocked by U0126 or MK2206 in pbMECs compared with AG group (*P* \< 0.05; [Fig. 9C and D](#fig9){ref-type="fig"}). In addition, stimulation with \[D-Lys3\]-GHRP-6, NF449, U0126, and MK2206 alone had no significant effect on cell proliferation compared with the NT control group. These results showed that cell proliferation induced by AG or UAG was likely mediated through a GHSR1a and Gαs signal cascade.

Discussion
==========

Our findings show that both AG and UAG increase the gene and protein expression of CSN2 in pbMECs of lactating cows. The ERK1/2 and AKT signal pathway that is activated by GHSR1a and Gαs likely mediates these effects.

The initiation of lactation dramatically alters the metabolism of many organs so that the mammary glands can be supplied with the nutrients necessary for milk protein synthesis ([@bib35]). Protein production is controlled by the complex interplay of peptide and steroid hormones, predominantly the lactogenic hormones: prolactin, insulin, and hydrocortisone. More recently, other hormones have been discovered in breast milk such as AG ([@bib27]). The third amino acid residue of AG, serine (Ser3), is modified by an acyl group; this modification is essential for AG biological activity. In addition to *n*-octanoyl AG, other forms of AG peptide exist, including UAG, which lacks an acyl modification, and other acylated AG species, such as *n*-decanoyl AG, whose Ser3 residue is modified by *n*-decanoic acid ([@bib33]). It has been shown that *n*-decanoyl AG was one of the active forms of the AG peptide and that it could interact with the receptor in a manner similar to that of *n*-octanoyl AG. A number of reports on the regulation of AG secretion in the context of energy metabolism and food intake in cows that did not distinguish between acyl-modified and des-acyl AG have been published ([@bib13], [@bib30], [@bib2], [@bib26], [@bib29], [@bib7]). In addition, the effects of *n*-octanoyl AG on plasma concentrations of glucose and milk yield and quality in lactation cows have been described in detail ([@bib13], [@bib26], [@bib9]). However, the effects and mechanisms of *n*-octanoyl AG and UAG in milk protein synthesis *in vitro* have not been examined. Thus, *n*-octanoyl AG and UAG were used in our experiment.

We first evaluated the effects of AG on the expression of CSN2 in pbMECs of lactation cows. With the exception of the epithelial cells of alveoli and ducts throughout the lactation in dairy goats ([@bib36]), our results demonstrated that AG and GHSR1a were expressed in pbMECs. We also find that only 10 ng/mL AG significantly increased the gene expression of *CSN2*. Western blot results showed that the expression of CSN2 protein was significantly higher in these pbMECs treated with a concentration range of 1--100 ng/mL compared with NT control group. Previous studies suggested that unlike AG, UAG is not acylated at Ser3 ([@bib4], [@bib5]), and its effect on the expression of CSN2 has not been elucidated. However, here we show for the first time that UAG, similar to AG, significantly stimulated the gene expression of *CSN2*. Although the expression of *CSN2* mRNA after treatment with UAG exhibited a similar tendency with AG-treated group, there are some different effects between AG and UAG. We observed significantly increased protein expression of CSN2 when treated with 1 ng/mL of AG compared with NT control group; however, there is no significantly increased when treated with UAG. Furthermore, highest protein expression of CSN2 was achieved in 10 ng/mL of AG, whereas 100 ng/mL for UAG. The cause of this results maybe that UAG is a full agonist of the GHSR1a, with activity in the high nanomolar range ([@bib8]). In a word, our results suggested that AG and UAG could directly modulate the expression of CSN2 in the cultured pbMECs, this is in agreement with ﬁndings in goat ([@bib36]).

The speciﬁc receptor mediating the signaling responses to AG or UAG in pbMECs is unknown. Cell-based assays have demonstrated that AG requires acylation at the Ser3 residue to activate GHSR1a at concentrations within the low-nanomolar range ([@bib11]). This evidence led to the assumption that the biological effects of UAG are independent of GHSR1a activation. However, a more recent study reported that UAG interacts with GHSR1a at concentrations within the high-nanomolar or micromolar range. Although some data indicate that UAG is a weak GHSR1a agonist, other data suggest that UAG is actually a full agonist of GHSR1a and induces similar maximal receptor stimulation as AG, such as the regulation of cell proliferation and glucose metabolism ([@bib3], [@bib24]). Thus, we investigated whether the effects of AG or UAG on the expression of CSN2 were dependent on GHSR1a. Our results showed that both AG- and UAG-induced expression of CSN2 were significantly blocked by \[D-Lys3\]-GHRP-6, an inhibitor of GHSR1a. Altogether, our *in vitro* results are consistent with the literature and suggest that UAG is an agonist of GHSR1a and regulates the expression of CSN2 in pbMECs.

GHSR1a belongs to the class A G-protein-coupled receptor (GPCR) family. When GHSR1a binds to the GPCR, a conformational change occurs in the GPCR, which allows it to activate an associated G-protein such as Gαs, Gαi/o, or Gαq/11 ([@bib6]). Here, we have investigated which G-protein subunit couples to GHSR1a in AG- and UAG-induced expression of CSN2 in pbMECs. We find that only NF449, the specific inhibitor of Gαs, significantly reduced both AG and UAG-induced expression of CSN2 at both the gene and protein levels in pbMECs, whereas PTX and YM-254890 had no effect (data not shown). This result revealed the selective coupling of activated GHSR1a to G-protein subtypes.

Previous studies demonstrated that AG is correlated with the expression of CSN2*in vivo* or *in vitro* in different species ([@bib9], [@bib22], [@bib36]). However, the mechanisms of this correlation are undefined. Downstream signaling of GHSR1a is mediated by several signaling pathways including the receptors ERK1/2 and AKT ([@bib8], [@bib31], [@bib6], [@bib25]). It is well known that ERK1/2 and AKT play important roles in the regulation of cell survival ([@bib31]). AG- or UAG-induced activation of ERK1/2 and AKT is observed in many cell types, such as pancreatic β-cell line HIT-T15 ([@bib6]), pancreatic β-cells, and macrophages ([@bib19]). To uncover the molecular mechanism underlying the tissue-specific response in GHSR1a-mediated intracellular signaling, we investigated the phosphorylation of ERK1/2 and AKT. In agreement with previous findings, stimulation by AG or UAG induces significant activation of ERK1/2 and AKT compared with NT control group ([@bib10]). However, increased phosphorylation of ERK1/2 or AKT induced by AG or UAG was suppressed after pre-incubated with the inhibitor of GHSR1a, \[D-Lys3\]-GHRP-6. Moreover, previous research demonstrated that G-protein signaling cascades play an important role in prolactin-induced synthesis of milk products ([@bib12], [@bib17]). AG binding to GHSR1a has been shown to activate intracellular second messengers coupled to Gαs, Gαi/o, and Gαq/11, leading to activation of AKT, ERK1/2, AMPK, or mTOR signal pathways ([@bib31]). GHSR1a couples to different intracellular signaling pathways depending on the cell type. Here, our results showed that only treatment with NF449 for 1 h inhibited the phosphorylation of ERK1/2 and AKT induced by AG or UAG in pbMECs. This observation is consistent with the report of Granata that Gαs is required for AG- or UAG-induced phosphorylation of ERK1/2 and AKT ([@bib10]).

To further determine whether the ERK1/2 and AKT pathway are required for the expression of CSN2 induced by AG or UAG, we examined the effect of U0126 and MK2206, which are specific inhibitors of ERK1/2 and AKT respectively. The chemical inhibition of ERK1/2 and AKT resulted in a significant suppression of AG- and UAG-induced expression of CSN2 in pbMECs, indicating that both AG and UAG stimulated the expression of CSN2 via activation of the ERK1/2 and AKT signaling pathways. Although previous studies indicate that mTOR and STAT5 signaling pathways play an important role in milk protein synthesis in the lactating cows ([@bib16]), here we are the first to demonstrate that activation of GHSR1a by AG or UAG may couple to Gαs and signals to ERK1/2 and AKT to increase CSN2 expression in pbMECs.

It has shown that both AG and UAG promote cell proliferation and inhibit apoptosis in pancreatic β-cells ([@bib10]), endothelial cells, and skeletal muscle cell ([@bib34]). Milk proteins are synthesized and excreted by MECs during lactation. We presume that the milk protein synthesis within the MECs may be regulated through cell proliferation. In agreement, our results also proved that both AG and UAG stimulate pbMECs proliferation in a dose-dependent manner at 24 h, even for 48 h. Pre-treatment with \[D-Lys3\]-GHRP-6 and NF449 abolishes AG- or UAG-induced cell proliferation in pbMECs. In addition, the ERK1/2 and AKT inhibitors U0126 and MK2206, respectively, also suppress cell proliferation induced by AG or UAG. These results are consistent with previous reports that activation of the ERK1/2 and AKT pathways regulate pbMEC number and activity ([@bib21]).

Collectively, our results demonstrate that GHSR1a is a Gαs-coupled receptor involved in the AG- and UAG-induced expression of CSN2 in pbMECs and that increased the expression of CSN2 induced by either AG or UAG are likely mediated by the phosphorylation of ERK1/2 and AKT signaling pathways.
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